

# Paul M Mckie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7190412/publications.pdf>

Version: 2024-02-01

43  
papers

2,455  
citations

236833

25  
h-index

315616

38  
g-index

45  
all docs

45  
docs citations

45  
times ranked

3059  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. <i>Biomarkers</i> , 2021, 26, 639-646.	0.9	7
2	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1267.	3.0	66
3	Artificial Intelligenceâ€“Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2576-2586.	1.4	15
4	Synchronous neurologyâ€“primary care collaboration in a medical home. <i>Neurology: Clinical Practice</i> , 2020, 10, 388-395.	0.8	1
5	Myocardial Aging, the Cardiac Atria, and BNP. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1801-1803.	1.2	5
6	Screening for cardiac contractile dysfunction using an artificial intelligenceâ€“enabled electrocardiogram. <i>Nature Medicine</i> , 2019, 25, 70-74.	15.2	686
7	Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. <i>Cephalalgia</i> , 2018, 38, 1841-1848.	1.8	18
8	The Fragility Index: a P-value in sheepâ€™s clothing?. <i>European Heart Journal</i> , 2017, 38, ehw495.	1.0	72
9	Effect of integrated community neurology on utilization, diagnostic testing, and access. <i>Neurology: Clinical Practice</i> , 2017, 7, 306-315.	0.8	10
10	Impact of electronic clinical decision support on adherence to guideline-recommended treatment for hyperlipidaemia, atrial fibrillation and heart failure: protocol for a cluster randomised trial. <i>BMJ Open</i> , 2017, 7, e019087.	0.8	6
11	NT-proBNP. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2437-2439.	1.2	69
12	Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 433-441.	2.9	22
13	MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results. <i>BMC Pharmacology &amp; Toxicology</i> , 2015, 16, .	1.0	1
14	Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure. <i>Current Heart Failure Reports</i> , 2015, 12, 7-14.	1.3	13
15	Circulating C-Type Natriuretic Peptide and Its Relationship to Cardiovascular Disease in the General Population. <i>Hypertension</i> , 2015, 65, 1187-1194.	1.3	35
16	Mâ€“Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics. <i>Journal of the American Heart Association</i> , 2014, 3, e000206.	1.6	30
17	Differential Cardiac versus Renal Response to Acute Volume Overload in Human Preclinical Systolic Dysfunction and Renal Dysfunction with the Combination of PDEV Inhibition and BNP Administration. <i>Journal of Cardiac Failure</i> , 2014, 20, S13.	0.7	0
18	High-Sensitivity Troponin I and Amino-Terminal Proâ€“B-Type Natriuretic Peptide Predict Heart Failure and Mortality in the General Population. <i>Clinical Chemistry</i> , 2014, 60, 1225-1233.	1.5	49

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of subcutaneous delivery of M-ANP: an innovative designer anp-based guanylyl cyclase activating peptide for hypertension. <i>Journal of the American Society of Hypertension</i> , 2014, 8, e33.	2.3	0
20	Abstract 17940: PDEV Inhibition + BNP Administration Enhanced the Cardiac but not the Renal Response to Acute Volume Overload in Human Preclinical Diastolic Dysfunction as Compared to PDEV Inhibition Alone. <i>Circulation</i> , 2014, 130, .	1.6	0
21	Relative Utility of Health ABC Risk Score, NT-proBNP and Systolic Function as Heart Failure Screening Tools in the General Community. <i>Journal of Cardiac Failure</i> , 2013, 19, S29.	0.7	0
22	Novel Protein Therapeutics for Human Preclinical Diastolic Dysfunction (Stage B Heart Failure): Chronic SQ BNP Administration. <i>Journal of Cardiac Failure</i> , 2013, 19, S65.	0.7	0
23	Aged Mediated Cardiac Fibrosis and Diastolic Impairment Is Associated with a Reduction in the Collagen Degrading Pathway and an Imbalance between the Natriuretic Peptide and the Renin-Angiotensin-Aldosterone Systems. <i>Journal of Cardiac Failure</i> , 2013, 19, S1.	0.7	1
24	B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2456-2460.	1.2	92
25	Human Hypertension Is Characterized by a Lack of Activation of the Antihypertensive Cardiac Hormones ANP and BNP. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1558-1565.	1.2	82
26	CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart. <i>PLoS ONE</i> , 2012, 7, e52422.	1.1	54
27	M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy. <i>Current Hypertension Reports</i> , 2012, 14, 62-69.	1.5	23
28	Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up Study. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1154-1160.	1.4	54
29	Pro-B-Type Natriuretic Peptide 108 Circulates in the General Community. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1386-1395.	1.2	65
30	A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community. <i>Journal of the American College of Cardiology</i> , 2011, 58, 629-636.	1.2	91
31	Impaired Natriuretic and Renal Endocrine Response to Acute Volume Expansion in Pre-Clinical Systolic and Diastolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2095-2103.	1.2	70
32	Corin Is Present in the Normal Human Heart, Kidney, and Blood, with Pro-B-Type Natriuretic Peptide Processing in the Circulation. <i>Clinical Chemistry</i> , 2011, 57, 40-47.	1.5	91
33	The Aging Heart, Myocardial Fibrosis, and its Relationship to Circulating C-Type Natriuretic Peptide. <i>Hypertension</i> , 2011, 57, 201-207.	1.3	95
34	Can a Cardiac Peptide Predict Mortality in Human Hypertension?. <i>Hypertension</i> , 2011, 57, 670-671.	1.3	5
35	Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F943-F952.	1.3	32
36	CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease. <i>Current Heart Failure Reports</i> , 2010, 7, 93-99.	1.3	33

#	ARTICLE	IF	CITATIONS
37	A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension. <i>Hypertension</i> , 2010, 56, 1152-1159.	1.3	40
38	The Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide for Death and Cardiovascular Events in Healthy Normal and Stage A/B Heart Failure Subjects. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2140-2147.	1.2	114
39	A Human Atrial Natriuretic Peptide Gene Mutation Reveals a Novel Peptide With Enhanced Blood Pressure-Lowering, Renal-Enhancing, and Aldosterone-Suppressing Actions. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1024-1032.	1.2	58
40	Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H1529-H1535.	1.5	54
41	Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide. <i>Hypertension</i> , 2006, 47, 874-880.	1.3	150
42	B-Type Natriuretic Peptide as a Biomarker Beyond Heart Failure: Speculations and Opportunities. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1029-1036.	1.4	83
43	Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3',5'-Monophosphate and Decreases Mean Arterial Pressure. <i>Circulation</i> , 2005, 112, 836-840.	1.6	63